P90 Use of procalcitonin to predict morbidity and mortality in COVID-19
| Autor: | S. Waring, A. Sethuraman, S. Kumar, U. Ekeowa, S. Kuckreja, G. Gamtkitsulashvili, S. Naik, Y. Narayan, R. Ragatha, A. D’Souza, Peter Russell, S. Jiwani, G. Collins, Muhammad Anwar, K. Patrick, O. Taylor |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
education.field_of_study
2019-20 coronavirus outbreak medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry Incidence (epidemiology) Population bacterial infections and mycoses Antimicrobial Procalcitonin Icu admission Internal medicine parasitic diseases Cohort Medicine business education hormones hormone substitutes and hormone antagonists |
| Zdroj: | COVID-19: clinical features and risk. |
| Popis: | P90 Figure 1The association of PCT in COVID-19 and patient morbidity and mortality.[Figure omitted. See PDF]ConclusionsHere, we report the largest single-centre study to date in analysing a UK-based population for procalcitonin in COVID-19. We observed a significant correlation between elevated initial levels of PCT and incidence of ICU admission and mortality within our cohort, thereby demonstrating promise for PCT as an effective prognostic marker. Using a higher cut-off for PCT ≥0.5µg/L increased mortality by almost 50%, but had no effect on morbidity. We suggest that a lower universal cut-off point for PCT should be used for detecting secondary bacterial infections and procalcitonin-guided antimicrobial therapy.ReferencesHu R, et al. International Journal of Antimicrobial Agents 2020;56(2):106051.Vazzana N, et al. Acta Clin Belg. 2020 Sep 23:1–5. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|